A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer

Area of Science:

• Gynecologic Oncology
• Cancer Genomics
• Molecular Pathology

Background:

• Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer.
• USC is characterized by frequent TP53 mutations and activation of specific signaling pathways, including PI3K/AKT/mTOR.
• Patients with USC often develop resistance to paclitaxel and carboplatin chemotherapy and have an immunosuppressive tumor microenvironment.

Purpose of the Study:

• To review the genetic mutations and signaling pathways implicated in uterine serous carcinoma.
• To discuss the challenges of chemoresistance and the immunosuppressive microenvironment in USC.
• To explore the potential of targeted therapies and immunotherapies for managing recurrent USC.

Main Methods:

• Review of genetic mutations in USC, including TP53, FBXW7, PIK3CA, and PP2R1A.
• Analysis of key signaling pathways involved in USC progression, such as CDK, HER2, and PI3K/AKT/mTOR.
• Evaluation of current treatment strategies and emerging therapeutic targets for USC.

Main Results:

• USC frequently harbors mutations in TP53, FBXW7, PIK3CA, and PP2R1A.
• Key signaling pathways like PI3K/AKT/mTOR are crucial in USC pathogenesis.
• Chemoresistance to paclitaxel and carboplatin, along with an immunosuppressive microenvironment, complicates USC treatment.
• Clinical trials targeting HER2/neu and WEE1 have shown promising survival benefits.

Conclusions:

• Targeted therapies, particularly those against HER2/neu and WEE1, offer potential for improving outcomes in USC.
• Developing novel targeted therapies and immunotherapies is crucial for overcoming chemoresistance and treating recurrent USC.
• Further research into the molecular underpinnings of USC is essential for advancing treatment strategies.